Effects of chemotherapy for prostatic carcinoma on T lymphocyte levels.
D000284:Administration, Oral; D000368:Aged; D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004912:Erythrocytes / Q000276:immunology; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007104:Immune Adherence Reaction; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology*; D012075:Remission, Spontaneous; D012756:Sheep / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D004054:Diethylstilbestrol; D003520:Cyclophosphamide; D005472:Fluorouracil